QuidelOrtho Corporation QDEL
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About QDEL
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
QuidelOrtho Corporation is a U.S.-based diagnostics company that develops and manufactures in vitro diagnostic technologies used in clinical laboratories, hospitals, physician offices, retail settings, and point-of-care environments. The company operates within the broader healthcare diagnostics and medical technology industries, with a focus on immunoassay, molecular diagnostics, clinical chemistry, transfusion medicine, and rapid diagnostic testing. QuidelOrtho was formed through the 2022 combination of Quidel Corporation and Ortho Clinical Diagnostics, creating a diversified diagnostics platform with broad global reach and an expanded product portfolio.
The company’s primary revenue drivers include diagnostic instruments, consumables, reagents, and testing services across infectious disease, blood typing, donor screening, and laboratory automation markets. Key product families include the Sofia, Savanna, and QuickVue diagnostic platforms from the former Quidel business, alongside Vitros systems and transfusion medicine offerings from Ortho Clinical Diagnostics. QuidelOrtho serves hospitals, reference laboratories, blood banks, public health agencies, and decentralized care providers. Its strategic positioning is supported by a large installed instrument base, recurring consumables revenue, broad regulatory clearances, and established relationships with healthcare systems worldwide.
Business Operations
QuidelOrtho organizes operations across major diagnostics categories that include rapid diagnostics, molecular diagnostics, immunohematology, clinical chemistry, and laboratory services. The company generates revenue through sales of diagnostic instruments, testing cartridges, reagents, assays, maintenance contracts, and laboratory consumables. A significant portion of recurring revenue is tied to consumable utilization on installed systems, particularly within the Vitros laboratory platform and transfusion medicine product lines. The company also benefits from long-term customer relationships with hospitals and laboratory networks that rely on integrated diagnostic workflows.
Operations span both domestic and international markets, with manufacturing, research, and commercial activities distributed across North America, Europe, and other international regions. QuidelOrtho controls a range of proprietary technologies including lateral flow diagnostics, immunoassay systems, molecular testing platforms, and automated clinical chemistry analyzers. The company maintains strategic collaborations with healthcare providers, distributors, and government entities, particularly in infectious disease surveillance and laboratory testing. Key subsidiaries and operational entities include Ortho Clinical Diagnostics, which remains central to the company’s laboratory diagnostics business.
Strategic Position & Investments
QuidelOrtho’s strategic direction has centered on integrating the legacy Quidel and Ortho Clinical Diagnostics businesses while expanding higher-margin recurring diagnostics revenue. Growth initiatives include menu expansion for molecular and immunoassay platforms, increasing adoption of decentralized testing systems, and advancing automation capabilities for clinical laboratories. The company has also emphasized operational efficiencies and cross-selling opportunities following the merger transaction that created QuidelOrtho.
Major investments have included continued development of the Savanna multiplex molecular testing platform and enhancements to the Vitros clinical laboratory ecosystem. The acquisition of Ortho Clinical Diagnostics materially expanded Quidel’s scale, global distribution capabilities, and exposure to hospital laboratory markets. QuidelOrtho also maintains involvement in emerging diagnostic areas tied to respiratory disease detection, syndromic testing, and next-generation point-of-care technologies. Public disclosures indicate continued investment in research and development intended to strengthen assay menus and support long-term recurring revenue growth.
Geographic Footprint
QuidelOrtho is headquartered in San Diego, California, and maintains a significant international operating footprint through manufacturing sites, commercial offices, and distribution networks. The company has substantial market presence across North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East and Africa. International operations became significantly broader following the integration of Ortho Clinical Diagnostics, which historically maintained strong penetration in global hospital laboratory markets.
The company’s products are used in numerous countries through direct sales channels and third-party distributors. QuidelOrtho maintains operational influence in developed healthcare systems as well as emerging markets where demand for diagnostic infrastructure and decentralized testing continues to expand. Its installed laboratory systems and transfusion medicine platforms provide ongoing exposure to international healthcare spending and hospital modernization initiatives.
Leadership & Governance
QuidelOrtho’s leadership team combines executives from both the legacy Quidel and Ortho Clinical Diagnostics organizations. The company’s governance structure emphasizes diagnostics innovation, operational integration, and global commercial expansion. Strategic priorities communicated by management have included strengthening recurring revenue streams, advancing product innovation, improving operational execution, and expanding customer adoption across decentralized and laboratory settings.
Key executives include:
- Brian J. Blaser – President and Chief Executive Officer
- Joseph M. Busky – Chief Financial Officer
- Jonathan Siegrist – Executive Vice President, Clinical Laboratory
- Kathleen Orland – Executive Vice President, General Counsel and Corporate Secretary
- Dawn Andrews – Executive Vice President, Research and Development
- Mike Iskra – Executive Vice President, Commercial Operations
The company’s leadership strategy has emphasized leveraging scale from the Quidel-Ortho combination, investing in diagnostic innovation, and maintaining a balanced portfolio spanning rapid testing, laboratory diagnostics, and transfusion medicine.